metformin/empagliflozin vs ranolazine
Side-by-side comparison of metformin/empagliflozin and ranolazine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .
Recommendation: Your healthcare provider may need to adjust your dosage and watch for signs of metformin toxicity.
Synjardy
Ranexa
Synjardy is a drug that combines empagliflozin and metformin. It helps lower blood sugar in people with type 2 diabetes, along with diet and exercise.
Ranolazine extended-release tablets help treat chronic angina (chest pain). It can be used with other heart medicines.
Synjardy is used to treat type 2 diabetes in adults and children 10 years and older. It helps control blood sugar levels when used with diet and exercise. Empagliflozin, one of the drugs in Synjardy, can also lower the risk of heart-related death in adults with heart disease. It can also lower the risk of heart failure and kidney problems in adults with heart failure or chronic kidney disease.
Ranolazine is used to treat chronic angina, which is chest pain that keeps coming back. It can help you have fewer angina episodes. You can take this medicine with other drugs like beta-blockers or nitrates.
Synjardy contains two medicines that work in different ways. Empagliflozin helps your kidneys remove sugar from your blood through urine. Metformin lowers the amount of sugar your liver makes and helps your body use insulin better.
Ranolazine works by affecting the sodium channels in your heart cells. This helps to improve blood flow to your heart. It reduces the amount of calcium in your heart, which can help prevent angina.
- • Urinary tract infections
- • Yeast infections of the vagina
- • Diarrhea
- • Nausea
- • Vomiting
- • Dizziness
- • Headache
- • Constipation
- • Nausea
- Feeling sick to your stomach 21,946
- Loose or watery stools 21,887
- High blood sugar 18,329
- Feeling tired 17,252
- Sudden damage to the kidneys 16,440
- Death 816
- Heart attack 640
- Chest pain 605
- Angina 594
- Stent placement 582
Metformin can cause a serious side effect called lactic acidosis. This is a buildup of lactic acid in your blood. It can be life-threatening. Get medical help right away if you have symptoms like feeling very weak, muscle pain, trouble breathing, stomach pain, dizziness, or a slow or irregular heartbeat.
Ranolazine can cause changes in your heart's electrical activity (QT prolongation). If you have kidney problems, your doctor should check your kidney function. If you develop kidney failure, stop taking ranolazine.
Synjardy may harm your unborn baby, especially during the second and third trimesters. Talk to your doctor if you are pregnant or plan to become pregnant. It is not recommended to breastfeed while taking Synjardy.
It is not known if ranolazine can harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if ranolazine passes into breast milk. Discuss with your doctor if you are breastfeeding.
How to Read This metformin/empagliflozin vs ranolazine Comparison
metformin/empagliflozin is classified in the Biguanide / SGLT2 Combination drug class, while ranolazine sits within the Late Sodium Current Inhibitor (Antianginal) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, metformin/empagliflozin has 95,854 submissions while ranolazine has 3,237. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to ranolazine stops the kidneys from filtering metformin out of the blood as quickly as they should. this can lead to high levels of metformin and a higher risk of side effects.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between metformin/empagliflozin and ranolazine - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.